English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 906128      Online Users : 734
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/7568


    Title: BPR000K, a novel Aurora kinase inhibitor
    Authors: Chao, YS;Hsu, JTA;Chen, CT;Yeh, TK;Pan, SL;Hsieh, HP
    Contributors: Institute of Biotechnology and Pharmaceutical Research
    Abstract: Aurora kinases A, B, and C, members of sereine/threonine kinase, are key mitotic regulators involved in maintaining the genomic integrity of daughter cells. Because over-expression of Aurora A and Aurora B is frequently associated with tumor genesis, these molecules have been targeted for cancer therapy. Here we describe the profile of BPR000K, a specific and potent small molecule inhibitor discovered by the Institutes of Biotechnology and Pharmaceutical Research, National Health Research Institutes, targeting the Aurora kinase.BPR000K showed potent in vitro Aurora kinase A inhibition (IC50: 41 nM) and caused 4N-DNA accumulation at low concentration (26 nM). Moreover, BPR000K exhibited anticancer activity against a broad spectrum of cancer cells (IC50: 10~500 nM against Colo205, TW039, HCT-116, MOLM-13 and MIA Paca-2). In HCT-116 xenograft model, BPR000K suppressed tumor growth up to 90% at 20 mg/kg twice a day for 10-day treatment by IV administration, and showed better antitumoral activity than the reference agent (VX-680 at 50 mg/kg). The body weight loss is less than 10% during the dosing period. BPR000K also exhibited significant tumor regression in vivo by IV administration at 50 mg/kg once a day for 10-day treatment in Colo205 and MIA Paca-2 xenograft models. BPR000K suppressed tumor growth up to 90% at 50 mg/kg twice a day for 10-day treatment by IV administration in pencreative cancer xenograft models.
    Date: 2013-04-07
    Relation: Abstracts of Papers - American Chemical Society. 2013 Apr 7;245:Article number 300-MEDI.
    Link to: http://abstracts.acs.org/chem/245nm/program/view.php?pub_num=300&par=MEDI
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000324303602320
    Appears in Collections:[謝興邦] 會議論文/會議摘要
    [徐祖安] 會議論文/會議摘要
    [趙宇生(2002-2013)] 會議論文/會議摘要
    [葉燈光] 會議論文/會議摘要
    [陳炯東] 會議論文/會議摘要
    [潘秀玲(2009-2013)] 會議論文/會議摘要

    Files in This Item:

    There are no files associated with this item.



    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback